# Class 3 Biowaivers

> **NCT01010698** · PHASE1 · COMPLETED · sponsor: **University of Maryland, Baltimore** · enrollment: 48 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** cimetidine (or acyclovir)

## Key facts

- **NCT ID:** NCT01010698
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2020-11-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01010698

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01010698, "Class 3 Biowaivers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01010698. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*